Indiana University Vector Production Facility
Indianapolis, IN
National Center
Compare AAV CDMOs in Asia
Compare AAV CDMOs in India
Compare Lentiviral CDMOs in Asia
Compare Lentiviral CDMOs in India
49 confirmed programs
· 12 sponsors
· Last scored 2026-10-29
66.3
Signal Score
○ FDA Inspections
✓ Clinical Trials (49)
○ SEC Filings
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: Indiana University Vector Production Facility
- Signal Score
- 66.3/100 (as of 2026-10-29)
- Quality Compliance
- Assessment pending
- Headquarters
- Indianapolis, IN
- Modalities
- AAV, Lentiviral
- Active Programs
- 49 confirmed from ClinicalTrials.gov across 12 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Indiana University Vector Production Facility
CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
71.7
49 active programs across 12 sponsors
Modalities: AAV, Lentiviral
18 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
49 active programs across 12 sponsors · Modalities: AAV, Lentiviral · 18 programs in advanced phases (Phase 2/3)
Programs
49
Sponsors12
ModalitiesAAV, Lentiviral
49 active programs across 12 sponsors
Modalities: AAV, Lentiviral
18 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07640139
Estimating the Impact of Obesity Medications on Clinical and...
NA
Enrolling By Invitation
View all 49 programs →
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability
68.0
Parent company: Indiana University
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Indiana University
Financial assessment: 68.0/100
Capacity
58.0
1 manufacturing site: Indianapolis, IN
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100
Sites: Indianapolis, IN
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Indianapolis, IN
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100
Clinical Activity 49 studies
NCT07168785
[18F]-AraG PET Imaging in LA HNSCC
EARLY_PHASE1
Not Yet Recruiting
NCT07761910
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for...
PHASE2
Recruiting
NCT06725550
Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0
NA
Recruiting
NCT07708714
Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In...
PHASE1/PHASE2
Recruiting
NCT07640139
Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes
NA
Enrolling By Invitation
NCT06915038
ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx
NA
Recruiting
NCT06508827
Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma
PHASE2
Withdrawn
NCT06513663
Exercise as Maintenance Therapy in Advanced Lung Cancer
NA
Terminated
NCT05757843
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
PHASE2
Withdrawn
NCT05899166
Carbohydrate Beta Cell Function and Glucose Control in Children With Diabetes
NA
Recruiting
NCT05460468
Neuromodulation of Memory in Aging
NA
Recruiting
NCT06511453
Acupressure in Patients With Sickle Cell Disease
NA
Active Not Recruiting
NCT04402593
Music Therapy For The Treatment Of Cisplatin Induced Tinnitus In Patients...
NA
Withdrawn
NCT05783297
Midwest TXTXT Scale up of an Evidence-Based Intervention to Promote HIV...
NA
Completed
NCT05100342
Prospective Validation of a Points Score System Predicting 30-day Survival
NA
Recruiting
NCT05119036
Adjuvant Treatment Deintensification After Transoral Surgery for Human...
NA
Completed
NCT05251337
Use of Aromatherapy to Reduce Symptom Burden
PHASE2
Completed
NCT03321760
SABR for T1-2a N1 NSCLC
PHASE2
Withdrawn
NCT04930055
Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)
NA
Terminated
NCT05045820
Integrative Medicine in Pain Management in Sickle Cell Disease
NA
Active Not Recruiting
+ 29 more studies
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source:
public careers pages
· Checked Nov 20, 2026
Frequently Asked Questions About Indiana University Vector Production Facility
How many clinical programs is Indiana University Vector Production Facility linked to?
Indiana University Vector Production Facility is associated with 49 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Indiana University Vector Production Facility's CDMO Signal Score?
Indiana University Vector Production Facility has a Signal Score of 66/100, based on quality, operations, financial stability, and capacity data.
Evaluating Indiana University Vector Production Facility for a manufacturing program?
Use the free AI matchmaker to compare Indiana University Vector Production Facility against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Genezen
Indianapolis, IN · Lexington, MA
Signal Score: 78.1
AAV, Lentiviral
Pharmaron
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 82.9
AAV, Lentiviral, Plasmid, mRNA
BioReliance (Merck)
Glasgow, UK · Rockville, MD
Signal Score: 80.3
AAV, Lentiviral, Biologics
Compare Indiana University Vector Production Facility with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.